Ann: BTX 1801 Kills Superbugs Without Resistance World-First, page-448

First 448 Last

Share
Profile

Follow
jackphil

231 Posts.

38

21/06/19

15:31

Post #: 39177493
Share

Originally posted by bernsta: ↑

So managed to have a nice conversation with Matt this afternoon - i scribbled down what I could, brief update below whilst some is fresh in my head and in front of me:

My questions and key takeaways:

Q) If BTX1801 works on animal wounds, would we expect it work on humans ?

A) Does not foresee any issues at all as the models are translated into human efficacy and the bugs are done in real life situations with the anti-microbal effect. Essentially the Phase 1 and 1B studies are already completed here as they are replicating the studies with AD and Acne. The bacteria forms no resistance. Indicated that they somewhat stumbled upon this little beauty and thinks this may actually be bigger then other products in terms of value. Mentioned a huge market cap alone for this product when compared to NXS valuation.

Q) Are we looking at a CR?

A) He could not have said NO any clearer - he said many brokers have approached him regarding this basically seeking a 20% placement and he's told them to buy on marke (and he admitted they needed the cash back then). With the R & D rebate and the cash on hand to come they are fully funded to phase 2 trials. He said he will let the results decide the price. He feels this put a strangle on the share price in the past, which is why it hasn't run as much as it should have. He wants the price to run and the data to do the talking.

Q) How did Vince come over?

A) He did a good 6-12 months due diligence prior - BOT did approach him, but scoring him is a huge bonus for the company. 12 months ago big pharma had no idea on CBD. BOT essentially has a 3 year head start on anyone in this space.

Q) Trials for phase 2 studies running on time ?

A) No issues with timing, all running on time and as expected, results expected to be released next quarter as mentioned. Going very well as planned.

Q) Are big pharma sniffing?

A) Has had many meetings with big pharma already. They all ask the same q'n - how do you do what you do? He laughs in response. Will let data do the talking. He plans to be back in 6-8 weeks and regularly come to Aus from now on.

There is more - but wanted to provide a brief update on key issues - he's obviously having a very big day with meetings. Was very nice of him to give me half an hour.

This company is extremely easy to get in contact with. Matt is extremely accommodating and I encourage holders to get in touch.

Have a fantastic weekend.

Expand

Fantastic news Bernsta. thanks for sharing . This is going to 40 plus by end July. As Matt had said let it run into the phase 2 results and if positive, US listing and shoot the lights out

BOT Price at posting: 19.0¢ Sentiment: Buy Disclosure: Held
15 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Update: Index pulls back from record highs | October 16, 2024

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

PME

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

BM8

Battery Age Minerals gets set to capitalise on critical mineral demand

KAU

Kaiser Reef reports new A1 untapped gold zone – flags move past 'remnant mining'

There are more pages in this discussion • 175 more messages in this thread...

First 448 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 35.5¢		Change -0.005(1.39%)		Mkt cap ! $654.2M

Open	High	Low	Value	Volume
36.0¢	36.5¢	35.5¢	$980.2K	2.724M

Buyers (Bids)

No.	Vol.	Price($)
17	625342	35.5¢

Sellers (Offers)

Price($)	Vol.	No.
36.0¢	292830	11

View Market Depth

No.	Vol.	Price($)
19	627185	0.355
11	505421	0.350
20	667232	0.345
14	300262	0.340
9	244525	0.335

Price($)	Vol.	No.
0.360	91067	9
0.365	436246	12
0.370	472324	8
0.375	398537	7
0.380	240248	9

Last trade - 14.31pm 16/10/2024 (20 minute delay)

BOT (ASX) Chart

Ann: BTX 1801 Kills Superbugs Without Resistance World-First, page-448

ASX Market Update: Index pulls back from record highs | October 16, 2024

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

Battery Age Minerals gets set to capitalise on critical mineral demand

Kaiser Reef reports new A1 untapped gold zone – flags move past 'remnant mining'

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: BTX 1801 Kills Superbugs Without Resistance World-First, page-448

Top Stories

ASX Market Update: Index pulls back from record highs | October 16, 2024

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

Battery Age Minerals gets set to capitalise on critical mineral demand

Kaiser Reef reports new A1 untapped gold zone – flags move past 'remnant mining'

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News